hyperCORE International, a network of clinical trial sites across North America, has announced Nicholas Focil as its new president. With nearly 20 years of experience in clinical operations leadership and strategic partnerships, Focil is expected to significantly contribute to hyperCORE's mission in the global clinical research arena. His background includes founding and leading FOMAT Medical Research, which has conducted Phase I–IV trials across more than 70 therapeutic areas, emphasizing ethical, high-quality, and diverse clinical data.
Focil's early career involved investigator-initiated lab work with a Nobel laureate and pioneering roles in pre-pivotal diabetes device trials at Medtronic MiniMed. His leadership at Diverse Research Solutions before founding FOMAT has earned him a reputation for promoting trial diversity and community engagement. The outgoing president, Carlos Orantes, praised Focil's appointment as a milestone for the network's leadership evolution, highlighting the strong foundation laid for hyperCORE's growth.
Focil expressed gratitude towards Orantes and previous presidents for their contributions to hyperCORE's journey. He emphasized the network's commitment to operational excellence, innovation, and patient-centered care. Looking forward, Focil is excited about the opportunity to enhance site capabilities, broaden trial reach, and deliver diverse, high-quality research beneficial to patients and sponsors. His appointment comes at a dynamic period of growth for hyperCORE and the clinical research field at large.
For more information on hyperCORE International and its initiatives, visit https://www.hypercoreinternational.com.
